Clinical trial
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's…
NCT00005579 · University of Vermont, Other · Completed
Key facts
| NCT number | NCT00005579 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia |
| Official title | Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia |
| Lead sponsor | University of Vermont, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | dolastatin 10 |
| Start date | Jun 1, 1998 |
| Completion | Feb 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: